Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma
These translational data demonstrating higher CD73 expression in tumors after neoadjuvant chemotherapy or CRT support potential combination strategies with CD73-targeted treatment in ESCC.
Authors
- Shigeki Sekine (ORCID: https://orcid.org/0000-0003-0884-8981)
- K. Murayama (ORCID: https://orcid.org/0000-0003-3301-9966)
- Philip L. Martin (ORCID: https://orcid.org/0009-0005-2584-0262)
- Ken Kato (ORCID: https://orcid.org/0000-0001-6993-5152)
- Shun Yamamoto (ORCID: https://orcid.org/0000-0002-9065-781X)
- Zachary A. Cooper (ORCID: https://orcid.org/0000-0003-1059-0940)
- Rakesh Kumar
- Ying Wang (ORCID: https://orcid.org/0009-0008-5862-2239)
Institutions
- AstraZeneca (France) (FR)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- Université Bourgogne Franche-Comté (FR)
- AstraZeneca (Japan) (JP)
- National Cancer Center Hospital East (JP)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1007/s12672-025-02179-x
- Citations
- 1
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.12